474791 | InSolution™ MG-132 - CAS 133407-82-6 - Calbiochem

474791
Price could not be retrieved
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited Availability Limited Availability
Discontinued
There is a newer version of this product
Limited Quantities Available
Availability to be confirmed
      Will advise
      View Pricing & Availability
         CompareClick To Print This Page

      Overview

      Key Spec Table

      Empirical FormulaCAS #
      C₂₆H₄₁N₃O₅133407-82-6

      Pricing & Availability

      Catalogue NumberAvailability Packaging Qty/Pack Price Quantity
      474791-1MG
      Retrieving availability...
      Limited Availability Limited Availability
      Discontinued
      There is a newer version of this product
      Limited Quantities Available
      Availability to be confirmed
          Will advise

          1 mg
          Retrieving price...
          Price could not be retrieved
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          474791-5MG
          Retrieving availability...
          Limited Availability Limited Availability
          Discontinued
          There is a newer version of this product
          Limited Quantities Available
          Availability to be confirmed
              Will advise

              5 mg
              Retrieving price...
              Price could not be retrieved
              Upon Order Completion More Information
              You Saved ()
               
              Request Pricing
              Description
              Catalogue Number 474791
              Brand Family Calbiochem®
              Synonyms Carbobenzoxy-L-leucyl-L-leucyl-L-leucinal, Z-LLL-CHO, Proteasome Inhibitor XI
              References
              References Meriin, A.B., et al. 1998. J. Biol. Chem. 273, 6373.
              Adams, J., and Stein, R. 1996. Ann. Rep. Med. Chem. 31, 279.
              Lee, D.H., and Goldberg, A.L. 1996. J. Biol. Chem. 271, 27280.
              Wiertz, E.J.H.J., et al. 1996. Cell 84, 769.
              Read, M.A., et al. 1995. Immunity 2, 493.
              Rock, K.L., et al. 1994. Cell 78, 761.
              Product Information
              CAS number 133407-82-6
              Form Liquid
              Formulation A 10 mM (1 mg/210 µl) or (5mg/1050 µl) solution of MG-132 (Cat. No. 474790) in DMSO.
              Hill Formula C₂₆H₄₁N₃O₅
              Chemical formula C₂₆H₄₁N₃O₅
              Molar Mass 475.6
              Reversible Y
              Applications
              Biological Information
              Primary Target proteasome
              Primary Target IC<sub>50</sub> 3 µM in inhibiting NF-κB activation
              Primary Target K<sub>i</sub> 4 nM as proteasome inhibitor
              Purity ≥98% by HPLC
              Physicochemical Information
              Cell permeable Y
              Dimensions
              Materials Information
              Toxicological Information
              Safety Information according to GHS
              Safety Information
              R Phrase R: 36/38

              Irritating to eyes and skin.
              S Phrase S: 26-36-45

              In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
              Wear suitable protective clothing.
              In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).
              Product Usage Statements
              Storage and Shipping Information
              Ship Code Blue Ice Only
              Toxicity Irritant
              Storage -20°C
              Protect from Light Protect from light
              Special Instructions Following initial thaw, aliquot and freeze (-20°C).
              Packaging Information
              Packaged under inert gas Packaged under inert gas
              Transport Information
              Supplemental Information
              Specifications

              Documentation

              MSDS

              Languages
              Danmark Deutschland Ellas
              English España France
              Italia Korea Magyarország
              Nederland  Norge Polska
              Portugal Suomi Sverige
              България

              Certificates of Analysis

              TitleLot Number
              474791

              Citations

              Title
            • Yolanda Fernandez, et al. (2006) Chemical Blockage of the Proteasome Inhibitory Function of Bortezomib: Impact on Tumor Cell Death. Journal of Biological Chemistry 281, 1107-1118.
            • Markus D. Lacher, et al. (2006) Transforming Growth Factor-{beta} Receptor Inhibition Enhances Adenoviral Infectability of Carcinoma Cells via Up-Regulation of Coxsackie and Adenovirus Receptor in Conjunction with Reversal of Epithelial-Mesenchymal Transition. Cancer Research 66, 1648-1657.
            • Liwei Chen, et al. (2005) Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Molecular Cancer Therapeutics 4, 1311-1319.
            • Emily I. Chen, et al. (2005) Maspin alters the carcinoma proteome. FASEB Journal in press,.
            • Siva Kumar Kolluri, et al. (2005) The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis. Procedings of the National Academy of Science 102, 2525-2530.
            • Zaibo Li, et al. (2005) VHL protein-interacting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF-1α. European Molecular Biology Organization Reports 6, 373-378.
            • Yasuyuki Miyake, et al. (2005) Novel splicing variant of mouse orc1 is deficient in nuclear translocation and resistant for proteasome-mediated degradation. Journal of Biological Chemistry 280, 12643-12652.
            • Chuan-Jin Wu, et al. (2005) TNF-α induced c-IAP1/TRAF2 complex translocation to a Ubc6-containing compartment and TRAF2 ubiquitination. European Molecular Biology Organization Journal 24, 1886-1898.
            • Zhigang Zhang, Jin-Ying Wu, William Hait and Jin-Ming Yang. (2004) Regulation of the stability of P-glycoprotein by ubiquitination.. Molecular Pharmacology 66, 395-403.
            • Gloria Bonuccelli, et al. (2003) Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins. American Journal of Pathology 163, 1663-1675.
            • Data Sheet

              Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

              Revision 03-June-2013 JSW
              Synonyms Carbobenzoxy-L-leucyl-L-leucyl-L-leucinal, Z-LLL-CHO, Proteasome Inhibitor XI
              Description Potent, reversible, and cell-permeable proteasome inhibitor (Ki = 4 nM). Reduces the degradation of ubiquitin-conjugated proteins in mammalian cells and permeable stains of yeast by the 26S complex without affecting its ATPase or isopeptidase activities. Activates c-Jun N-terminal kinase (JNK1) and inhibits NF-κB activation (IC50 = 3 µM).
              Form Liquid
              Formulation A 10 mM (1 mg/210 µl) or (5mg/1050 µl) solution of MG-132 (Cat. No. 474790) in DMSO.
              Intert gas (Yes/No) Packaged under inert gas
              CAS number 133407-82-6
              Molar mass 475.6
              Chemical formula C₂₆H₄₁N₃O₅
              Purity ≥98% by HPLC
              Storage -20°C
              Protect from light
              Special Instructions Following initial thaw, aliquot and freeze (-20°C).
              Toxicity Irritant
              References Meriin, A.B., et al. 1998. J. Biol. Chem. 273, 6373.
              Adams, J., and Stein, R. 1996. Ann. Rep. Med. Chem. 31, 279.
              Lee, D.H., and Goldberg, A.L. 1996. J. Biol. Chem. 271, 27280.
              Wiertz, E.J.H.J., et al. 1996. Cell 84, 769.
              Read, M.A., et al. 1995. Immunity 2, 493.
              Rock, K.L., et al. 1994. Cell 78, 761.
              Citation
            • Yolanda Fernandez, et al. (2006) Chemical Blockage of the Proteasome Inhibitory Function of Bortezomib: Impact on Tumor Cell Death. Journal of Biological Chemistry 281, 1107-1118.
            • Markus D. Lacher, et al. (2006) Transforming Growth Factor-{beta} Receptor Inhibition Enhances Adenoviral Infectability of Carcinoma Cells via Up-Regulation of Coxsackie and Adenovirus Receptor in Conjunction with Reversal of Epithelial-Mesenchymal Transition. Cancer Research 66, 1648-1657.
            • Liwei Chen, et al. (2005) Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Molecular Cancer Therapeutics 4, 1311-1319.
            • Emily I. Chen, et al. (2005) Maspin alters the carcinoma proteome. FASEB Journal in press,.
            • Siva Kumar Kolluri, et al. (2005) The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis. Procedings of the National Academy of Science 102, 2525-2530.
            • Zaibo Li, et al. (2005) VHL protein-interacting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF-1α. European Molecular Biology Organization Reports 6, 373-378.
            • Yasuyuki Miyake, et al. (2005) Novel splicing variant of mouse orc1 is deficient in nuclear translocation and resistant for proteasome-mediated degradation. Journal of Biological Chemistry 280, 12643-12652.
            • Chuan-Jin Wu, et al. (2005) TNF-α induced c-IAP1/TRAF2 complex translocation to a Ubc6-containing compartment and TRAF2 ubiquitination. European Molecular Biology Organization Journal 24, 1886-1898.
            • Zhigang Zhang, Jin-Ying Wu, William Hait and Jin-Ming Yang. (2004) Regulation of the stability of P-glycoprotein by ubiquitination.. Molecular Pharmacology 66, 395-403.
            • Gloria Bonuccelli, et al. (2003) Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins. American Journal of Pathology 163, 1663-1675.